Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.

Mithra Pharmaceuticals SA

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women’s Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, Mithra is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

S.R.I.W.

Mithra

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel. For more information please read our latest press release: https://lnkd.in/eeJ4ZGDG

The entire Mithra team wishes you all a fun, relaxing and joyous end of year! We look forward to working with you in 2024!

Mithra announces that it has completed a Pediatric study of ESTELLE® in adolescent patients. For more information, we invite you to read the latest press release: https://lnkd.in/dHz-Ud7Z #mithra #womenshealth

Season's Greetings from Mithra! #womenshealth #seasonsgreetings

Our CEO David Solomon and Head of Investor Relations & Communications, Alex Sokolowski, PhD will be at the 42nd J.P. Morgan Healthcare Conference in San Francisco, CA, USA from the 8th to the 11th of January 2024, participating in various events and hosting meetings at the largest healthcare investment symposium in the industry! This will enable them to further connect to global industry leaders, innovative technology creators and members of the investment community. If you are interested in meeting with them there, please send an email to our team at investorreations@mithra.com.

David Solomon, Mithra’s CEO and Alex Sokolowski, PhD, Head of IR & Communications wrapped up a four city Investor Roadshow tour to Brussels, Luxembourg, Geneva and Zurich. It was a great opportunity to discuss Mithra, Women’s Health, and all the exciting things to come. We invite you to reach out to the Investor Relations team via investorrelations@mithra.com if you have any questions.

Mithra and Gedeon Richter are proud to announce they have signed binding Head of Terms to commercialize ESTELLE® and DONESTA® in China. For more information we invite you to read our latest press release https://bit.ly/4a4uiK3

Key to Mithra’s operations is our core asset estetrol (E4). Estetrol is the active ingredient in two of our innovative products, ESTELLE® and the investigational DONESTA®. It is a natural estrogen produced by the fetus during pregnancy. 

Estetrol has a unique mode of action that results in an improved benefit/risk profile compared to other currently available estrogens. We believe it represents a major breakthrough in women’s health. 

Find out more about estetrol here: https://lnkd.in/e9ZuBgaU

#Mithra #biotech #biopharma #ReproductiveHealth #innovation

We are looking forward to presenting at the ESG - European Society of Gynecology Congress on Friday 01 December and Saturday 02 December in Amsterdam
Our presentations will showcase the key role of estrogens in women’s health, including our core asset Estetrol (E4). 
To find out more, please visit: https://bit.ly/47LrcZI
#ESG #WomensHealth #estrogen #estetrol #biotech

Our team had a very productive visit to London for 4 intense days of conferences and events last week.
It was great to connect with other industry leaders, investors and peers. Thank you to Jefferies, ICR Consilium, LSX - partnering for Life Science eXecutives, Stifel Financial Corp. and Goodwin who made it all happen! 
#WomensHealth #JefferiesHealthcare #LSX #ICRConsiliumHC #Lifescience

Metric
Company Name	Mithra Pharmaceuticals SA	LégiaPark
Symbol	MITRA
MSH ID	COM:MITHRA	BE:LEGIAPARK
Market	STOCKS	PRIVATE
Sector	Healthcare	Commercial & Professional Services
Industry	Drug Manufacturers - Specialty & Generic	Life Sciences
Country	BE	BE
Stage
Employee Count	270
Website	mithra.com	legiapark.be
LinkedIn		l%C3%A9giapark
Founders

Metric
Market Cap	15.56M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	42.30M
Revenue (LTM)
Revenue (NTM)
Gross Profit	6.31M
EBITDA	-60.15M
Operating Income	-73.02M
Net Income	-182.76M
EPS	-2.64
Diluted EPS	-2.64
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	99.75
28-Day Growth Score	65.63
90-Day Growth Score	63.69
365-Day Growth Score	92.37

Metric
Gross Profit Margin	0.15
Operating Profit Margin	-1.74
EBITDA Margin	-1.42
Net Profit Margin	-4.32
Return on Equity	3.10
Return on Assets	-0.61
Return on Capital Employed	-0.38

COM:MITHRA

Mithra Pharmaceuticals SA

Last Close

0.22

23/07 20:00

Market Cap

14.93M

Beta: -

Volume Today

82.37K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.87
P/B Ratio	1.54
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.40
EV Multiple	3.16

Metric
Days Sales Outstanding	361.74
Days Payables Outstanding	589.94
Days Inventory Outstanding	515.91
Operating Cycle	843.98
Cash Conversion Cycle	212.87
Asset Turnover	0.14

Metric
Operating Cash Flow	-2.30M
Free Cash Flow	-2.30M
Cash Flow to Debt	-0.01
Operating Cash Flow/Sales	-0.05
Free Cash Flow Yield	-1.13

Metric
Cash & Equivalents	9.46M
Accounts Receivable
Inventory	50.87M
Goodwill	5.51M
Debt to Capitalization	2.45
Debt to Assets	0.52
Current Ratio	1.12
Quick Ratio	0.43

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03
R&D to Revenue	0.96
SG&A to Revenue	0.22